Eli Lilly's Obesity Drug Sales Surge Internationally
Eli Lilly is experiencing significant growth in its obesity drug business outside of the U.S., with international GLP-1 sales more than tripling in 2025 and again in Q1 2026. This overseas expansion has contributed to a strong stock performance, outpacing both pharmaceutical peers and broader market indices over three years.
Topics: global market expansion GLP-1 drugs obesity treatments stock performance